Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1? expression in non-small cell lung carcinoma

文献类型： 外文期刊

第一作者： Fu, Jijun

作者： Fu, Jijun;Chen, Minshan;Huang, Lijuan;Li, Songpei;Li, Zhan;Pan, Qianrong;Lv, Sha;Yang, Xiangyu;Wang, Ying;Zhang, Jianye;Lei, Xueping;Zeng, Wenjuan;Yi, Mengmeng

作者机构：

关键词： Non-small cell lung carcinoma; Angiogenesis inhibitor; Apigenin; HIF-1?; Lung squamous carcinoma

期刊名称：CHEMICO-BIOLOGICAL INTERACTIONS （ 影响因子：5.168； 五年影响因子：4.924 ）

ISSN： 0009-2797

年卷期： 2022 年 361 卷

页码：

收录情况： SCI

摘要： Tumor angiogenesis inhibitors such as Bevacizumab, Ramucirumab and Endostar have been applied to the therapy of non-small cell lung carcinoma (NSCLC) patients, especially for lung adenocarcinoma (LUAD). However, several safe concerns such as neutropenia, febrile neutropenia and hypertension pulmonary hemorrhage limit their further development. And they often showed poor efficacy and serious side effect for lung squamous cell carcinoma (LUSC) patient. Thus, identification of effective and safe tumor angiogenesis inhibitor for NSCLC therapy is warranted. Apigenin is a bioflavonoid with potential anti-tumor effect and perfect safety, but its effect on tumor angiogenesis and underlying mechanism are still unclear. Herein, we found that apigenin not merely suppressed endothelial cells related motilities but also reduced pericyte coverage. Further research showed that apigenin had strong suppressive activity against HIF-1 alpha expression and its downstream VEGF-A/VEGFR2 and PDGF-BB/PDGF beta R signaling pathway. Apigenin also reduced microvessel density and pericyte coverage on the xengraft model of NCI-H1299 cells, leading to suppression of tumor growth. Moreover, apigenein showed perfect anti-angiogenic effect in xengraft model of LUSC cell NCI-H1703 cells, indicating it may be developed into a potential angiogenesis inhibitor for LUSC patient. Collectively, our study provides new insights into the antitumor mechanism of apigenin and suggests that apigenin is a safe and effective angiogenesis inhibitor for NSCLC therapy.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序